Table 2.
Baseline characteristics of the included compounds.
| Characteristic | Total (N = 81) |
|---|---|
| n (%) | |
| Vaccine | |
| Yes | 28 (34.6) |
| No | 53 (65.4) |
| Combination drug | |
| Yes | 19 (23.5) |
| No | 62 (76.5) |
| Pathogen(s) targeted | |
| Virus | 53 (65.4) |
| Bacteria | 25 (30.9) |
| Fungi, other | 3 (3.7) |
| Outbreak setting | |
| EID | 23 (28.4) |
| Non-EID | 58 (71.6) |
| Type of sponsor-investigator of phase 1 trial | |
| Academic | 2 (2.5) |
| Pharmaceutical | 73 (90.1) |
| Governmental | 6 (7.4) |
| CMA | |
| Yes | 11 (13.6) |
| No | 70 (86.4) |
| Orphan drugs | |
| Yes | 8 (9.9) |
| No | 73 (90.1) |
| Accelerated assessment | |
| Yes | 6 (7.4) |
| No | 75 (92.6) |
| Type of disease | |
| HIV | 15 (18.5) |
| COVID-19 | 12 (14.8) |
| Hepatitis (A-E) | 12 (14.8) |
| Influenza | 5 (6.2) |
| DR-TB | 3 (3.7) |
| Ebola virus disease | 3 (3.7) |
| Other bacterial diseasea | 22 (27.2) |
| Otherb | 9 (11.1) |
EID; Emerging infectious disease. CMA; Conditional marketing authorisation. DR-TB; drug-resistant tuberculosis.
a
Including vaccines targeting meningococci, pneumococci, and Vibrio cholera, and antibiotics or monoclonal antibodies targeting Gram-negative bacterial infections, respiratory tract infections, community acquired bacterial infections, intra-abdominal infections, and anthrax.
b
Including vaccines targeting human papilloma virus, a combination of diphtheria/acellular pertussis/tetanus/polio/haemophilus influenzae b/hepatitis B, poxviridae infections, herpes zoster, and dengue, and antiviral targeting cytomegalovirus, poxviridae infections, and antimycotics targeting aspergillosis.